UBS O'Connor’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.15M | Sell |
39,978
-635
| -2% | -$18.3K | 0.06% | 180 |
|
|
2025
Q1 | $1.36M | Buy |
40,613
+12,926
| +47% | +$434K | 0.04% | 146 |
|
|
2024
Q4 | $1.42M | Buy |
27,687
+2,994
| +12% | +$153K | 0.04% | 195 |
|
|
2024
Q3 | $1.26M | Sell |
24,693
-428
| -2% | -$21.9K | 0.03% | 246 |
|
|
2024
Q2 | $1.13M | Buy |
25,121
+19,100
| +317% | +$855K | 0.03% | 276 |
|
|
2024
Q1 | $282K | Sell |
6,021
-4,017
| -40% | -$188K | 0.01% | 359 |
|
|
2023
Q4 | $357K | Sell |
10,038
-16,115
| -62% | -$573K | 0.01% | 367 |
|
|
2023
Q3 | $778K | Sell |
26,153
-30,000
| -53% | -$892K | 0.01% | 347 |
|
|
2023
Q2 | $1.01M | Buy |
56,153
+22,732
| +68% | +$410K | 0.02% | 378 |
|
|
2023
Q1 | $537K | Buy |
+33,421
| New | +$537K | 0.01% | 447 |
|
|
2022
Q4 | – | Sell |
-90,460
| Closed | -$1.78M | – | 77 |
|
|
2022
Q3 | $1.78M | Buy |
90,460
+3,000
| +3% | +$58.9K | 0.02% | 651 |
|
|
2022
Q2 | $1.63M | Buy |
+87,460
| New | +$1.63M | 0.02% | 686 |
|